Critical Survey: Fulgent Genetics (NASDAQ:FLGT) vs. Decision Diagnostics (OTCMKTS:DECN)

Decision Diagnostics (OTCMKTS:DECN) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Decision Diagnostics and Fulgent Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decision Diagnostics	0	0	0	0	0.00
Fulgent Genetics	1	2	2	0	2.20

Fulgent Genetics has a consensus price target of $27.00, indicating a potential upside of 47.46%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Decision Diagnostics.

Risk and Volatility

Decision Diagnostics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation and Earnings

This table compares Decision Diagnostics and Fulgent Genetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A
Fulgent Genetics	$322.67 million	1.61	-$60.51 million	($2.39)	-7.66

Decision Diagnostics has higher earnings, but lower revenue than Fulgent Genetics.

Profitability

This table compares Decision Diagnostics and Fulgent Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decision Diagnostics	N/A	N/A	N/A
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Summary

Fulgent Genetics beats Decision Diagnostics on 6 of the 10 factors compared between the two stocks.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.